Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
HELLENIC DYNAMICS PLC Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.	United Kingdom	HELD
HEMOGENYX PHARMACEUTICALS PLC Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.	United Kingdom	HEMO
HEM Pharma Inc. Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.	South Korea	376270
Hemp Health Spolka Akcyjna A vertically integrated supplier of medical cannabis raw material for the Polish market.	Poland	HMP
Herantis Pharma Oyj Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.	Finland	HRTIS
HERON THERAPEUTICS, INC. /DE/ Develops and commercializes therapies for acute care and oncology to manage pain and nausea.	United States of America	HRTX
HIGH TECH PHARM CO.,LTD. Global manufacturer of carbapenem antibiotic APIs for regulated markets.	South Korea	106190
HIKMA Pharmaceuticals PLC Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.	United Kingdom	HIK
HISAMITSU PHARMACEUTICAL CO.,INC. A global leader in transdermal drug delivery systems for OTC and prescription pain relief.	Japan	4530
HLB Genex, Inc. Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.	South Korea	187420